Shots:

• The approval is based on P-III RA-BEACON study results assessing Olumiant vs PBO in 527 patients with inadequate response or intolerance to one or more TNF inhibitor therapies
• P-III RA-BEACON study results: ACR20 (49% vs 27%) physical function based on the Health Assessment Questionnaire Disability Index (HAQ-DI) before/ after treatment (1.71- 1.78/ 1.31- 1.59)
• Olumiant (baricitinib- 2mg) is an oral drug indicated for patients with RA who have inadequate response to TNF antagonist therapies and is approved in 50 countries including the US- EU and Japan. In Dec-2009 Lilly and Incyte collaborated to develop and commercialize Olumiant for inflammatory and autoimmune diseases

Ref: Eli Lilly | Image: Eli Lilly